Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Kenya

Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial Aim 2

Highly subsidized first-line antimalarials (artemisinin combination therapy or ACT) are available over the counter in the private retail sector in most malaria-endemic countries. Overconsumption of ACTs purchased over the counter is rampant due to their low price, high perceived efficacy, and absence of diagnostic tools to guide drug use. The ultimate goal of the proposed work is to improve antimalarial stewardship in the retail sector, which is responsible for distributing the majority of antimalarials in sub-Saharan Africa. Through a combination of diagnosis and treatment subsidies and provider-directed incentives, this approach will align provider and customer incentives with appropriate case management and thereby improve health outcomes.

The main objective of this study (Aim 2) is to test two key interventions in a random sample of private medicine retail outlets in Kenya. This will be a cluster-randomized controlled trial where the cluster is a private retail outlet that stocks and sells WHO quality-assured ACTs. This three-arm study will test 1) a consumer-directed intervention in the form of a diagnosis-dependent ACT subsidy, 2) both a provider-directed incentive for testing and a client-directed intervention in combination against 3) a comparison arm. Outlets in all three arms will offer malaria diagnostic testing to customers who wish to purchase one. Information for the primary and secondary outcomes will be collected during exit interviews with eligible customers. The primary outcome will be the proportion of ACTs sold to customers with a positive diagnostic test. The main secondary outcome will be the proportion of suspected malaria cases presenting to the retail outlet that are tested. Other secondary outcomes include adherence to the RDT result amongst those tested (defined as taking a quality-assured ACT following a positive test and refraining from taking an ACT following a negative test) and appropriate case management for all suspected malaria cases (proportion tested and adhered among all suspected cases).

Study Overview

• Status: Completed
• Conditions: Malaria; Febrile Illness
• Intervention / Treatment: Other: Testing incentive; Other: Conditional artemisinin combination therapy subsidy

Detailed Description

RATIONALE:

The investigators hypothesize that decision-making in the retail sector is influenced primarily by price (or profit) supplemented by individual beliefs or preferences. Information from a diagnostic test, when available, plays only a minor role in the decision-making landscape. In response to this, the investigators propose to test a scalable, policy-relevant strategy that integrates testing and treatment subsidies and makes ACT subsidies available only to customers with a positive malaria test. Differential pricing based on the results of the diagnostic test will align consumer and provider incentives (price and profit) with testing and appropriate ACT use. This approach will also ensure that public subsidies are directed at confirmed malaria cases thereby enhancing the sustainability of such programs. By allocating subsidy dollars across both testing and conditional treatment (rather than universal, treatment-only subsidies), the investigators can reduce the cost of subsidizing malaria treatment and improve targeting of ACTs without compromising access.

OBJECTIVES:

This goal of the proposed work is to improve antimalarial stewardship in the retail sector, which has the largest market share of antimalarials in sub-Saharan Africa. In this study (Aim 2) the investigators will use a cluster randomized controlled trial to measure the impact of two innovative interventions - a provider-directed incentive for offering malaria rapid diagnostic tests to suspected malaria cases and a consumer-directed diagnosis dependent ACT subsidy (conditional ACT subsidy). The unit of randomization will be the private medicine outlet (cluster).

STUDY DESIGN:

The study will be a cluster-randomized controlled trial with three arms. The original study design was for a four-arm trial (an additional arm that would have tested the provider-directed incentive alone), however preliminary data from the study area indicated that the study may not be powered to measure the effect of a four arm study. No participants were enrolled prior to finalization of the study design, and all clusters will be randomized to one of the three remaining study arms only (1) control, 2) client-directed intervention, and 3) combined client- and provider-directed intervention). See Section 4.4 Statistical Design and Power for complete detail.

STUDY POPULATION:

The study will be conducted in Kenya, a country with high malaria burden. Kenya has the programmatic goal of universal access to prompt parasitological confirmation before treatment and have endorsed the use of malaria RDTs in the public health sector at all levels of care. However, very high rates of treatment in the retail sector undermine the explicit policy that all malaria cases should be confirmed by parasitological diagnosis. In Kenya, retail outlets currently do not conduct RDTs and emphasis has been placed on implementing community case management for malaria through public-sector community health workers (including conducting RDTs).

The specific study site will be western Kenya (Bungoma County and Trans Nzoia county).

STUDY PROCEDURES:

A complete sampling frame of eligible retail outlets will be made for the site. Outlets will be eligible if they regularly carry quality-assured, subsidized ACTs. Attendants who dispense medicines at each outlet will be trained to correctly and safely perform RDTs. They will receive an initial small start-up stock of RDTs and will be given contact information for RDT wholesalers who can provide replenishment stocks on demand. In addition, all attendants will be trained to use a mobile reporting app that captures basic information about suspected malaria cases. This app will not be used to assess outcomes, but will be an important monitoring tool and serve as the conduit for all payments according to the arm assignment.

Following training, shops will be randomized to one of the three arms:

• Arm 1 (control): RDTs available at study-recommended price, providers trained on mobile app
• Arm 2 (client-directed intervention): ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
• Arm 3 (client-directed and provider-directed intervention): providers are reimbursed for each RDT and consumers with a positive test are eligible for a subsidy on a quality-assured ACT. RDTs are available at study recommended price.

Customers who come to a participating outlet in any arm with fever or suspected malaria are eligible for an RDT at the study-recommended price and, in arms 2 and 3, a conditional ACT subsidy when the RDT is positive. Attendants will be trained to recognize danger signs and refer those individuals to a health facility for immediate care. Customers purchasing medicine on someone's behalf or those who have already had a malaria test will not be eligible for RDT testing or conditional subsidies.

Study outcome measures will be collected by interviewing a random sample of customers leaving participating shops (exit interviews). A team of field interviewers will be trained in each site and will be assigned to participating outlets on random days in a month. Both the day of the month and the interviewer assigned to the specific outlet will be randomized in order to balance data collection across interviewers and arms and to minimize the observer effect. Each outlet will be visited thrice in a month and the interviewer will enroll eligible participants in succession until they have completed 3-4 interviews. Ten customers per month per outlet are needed to reach a sample size of 170 interviews per outlet in 15 months of data collection. Exit interviews will capture information about customer demographics, symptoms of their current illness, whether they had a malaria diagnostic test at the outlet or elsewhere, how much they paid for the test, the results of the test, and the drug(s) they purchased. Customers will be eligible to participate in the exit interview if s/he was seeking drugs for him/herself or their minor child older than one year of age and the child is physically present, s/he had a febrile illness or suspected malaria, and s/he agrees to be interviewed.

Study monitoring will be continuous throughout the study period using the mobile app. Study staff will regularly review reporting data captured by the mobile app. In particular, pictures of RDTs will be reviewed alongside results reported by outlet attendants to ensure correct use and interpretation of the RDTs. In addition, exit interviews will be summarized monthly by outlet and compared to the data submitted via the app. This monitoring step will allow us to identify major discrepancies between actions reported by the shop and those reported by the customers such as testing rates, RDT positivity rates, dispensing of qualified ACTs and prices charged for RDTs and ACTs.

SAMPLE SIZE AND POWER:

The investigators calculated power based on a cluster randomized two-sample two-tailed t-test for the comparison of two proportions. The investigators calculated power for differences in the primary outcome for each of the two comparisons of interest noted above. With a sample of 170 exit interviews per outlet (40 outlets in Kenya), the investigators will have >90% power to detect a minimum difference between Arms 1 (control) and 3 (combined interventions) in the primary outcome of 16 percentage points. The investigators will also have >80% power to detect a minimum difference of 11 percentage points for the main secondary comparison of interest (testing uptake).

The sample size estimates correspond to a total of 6800 exit interviews with clients in Kenya. Since not everyone interviewed will have purchased an ACT, estimates account for the fact that only a subset will enter into the analysis for the primary outcome. The investigators will have a team of 8 data collectors and each data collector will conduct approximately 50-60 interviews per month. Exit interviews should take 15 months to complete.

See Section 4.4 Statistical Design and Power for comprehensive description of sample size, power and statistical analysis.

SUBJECT CONFIDENTIALITY:

Customers leaving the shop will be approached by the field interviewer to ask if they are interested in participating in a short interview. If they agree, then they will be taken to a private area and the study will be explained to them. Once they provide consent, the interviewer will record the details of their illness and treatment at the outlet. No participant identifiers will be recorded in the electronic data collection form. This limits the possibility of identifying the source of any health information (See Protection of Human Subjects Section 3.3).

• Study Type: Interventional
• Enrollment (Actual): 5696
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Kenya
  • Eldoret, Kenya
    • Moi University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

All clients attending a participating outlet on the day selected for exit interviews will be eligible to be screened for inclusion into the interview sample.

Inclusion Criteria:

• Participants with fever, or history of fever in the last 48 hours, or suspects they may have malaria
• Individual with malaria-like illness must be present at recruitment
• Older than one year of age

Exclusion Criteria:

• Any individual with signs of severe illness requiring immediate referral
• Individuals who have taken an antimalarial in the last seven days, including for the current illness
• Patients <18 years without a parent or legal guardian present

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Arm 1 (control); RDTs available at study-recommended price, providers trained on mobile reporting app
Experimental: Arm 2 (client-directed intervention); ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price	Other: Conditional artemisinin combination therapy subsidy; An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
Experimental: Arm 3 (client-directed and provider-directed intervention); providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price	Other: Testing incentive; A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.; Other: Conditional artemisinin combination therapy subsidy; An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ACT (Artemisinin Combination Therapy) Consumption by True Malaria Cases	Number of participants who purchased ACTs and were malaria test-positive. Malaria test-positivity was based on mRDT testing testing at the outlet or documented testing brought to the facility.	Day of enrollment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Use of Malaria Rapid Diagnostic Test	Number of participants with suspected malaria cases presenting to the retail outlet that are tested.	Day of enrollment
Adherence to the RDT (Rapid Diagnostic Test) Result Among All Those Tested in the Shop	The number of tested participants who are adherent where adherence to the test result is defined as taking a quality-assured ACT if the RDT is positive or taking another drug (or no drug) if the test is negative.	Day of enrollment
Appropriate Case Management	Number of all participants with suspected malaria cases that are managed appropriately (tested for malaria, and use ACT following a positive test and do not purchase an ACT after a negative test)	Day of enrollment
ACT (Artemisinin Combination Therapy) Use Among Untested Clients	Number of participants who are not tested for malaria and purchased an ACT, among those who did not test in the shop, do not have documentation of a test, and purchased any antimalarial at the shop.	Day of enrollment

Collaborators and Investigators

• Sponsor: Duke University
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID); Clinton Health Access Initiative Inc.; Moi University
• Investigators: Principal Investigator: Wendy P O'Meara, PhD, Duke University

Publications and helpful links

General Publications

• Woolsey AM, Simmons RA, Woldeghebriel M, Zhou Y, Ogunsola O, Laing S, Olaleye T, Kipkoech J, Rojas BM, Saran I, Odhiambo M, Malinga J, Ambani G, Kimachas E, Fashanu C, Wiwa O, Menya D, Laktabai J, Visser T, Turner EL, O'Meara WP. Incentivizing appropriate malaria case management in the private sector: a study protocol for two linked cluster randomized controlled trials to evaluate provider- and client-focused interventions in western Kenya and Lagos, Nigeria. Implement Sci. 2021 Jan 20;16(1):14. doi: 10.1186/s13012-020-01077-w. Erratum In: Implement Sci. 2021 Mar 16;16(1):27. Implement Sci. 2022 Sep 15;17(1):61.

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2021
• Primary Completion (Actual): August 31, 2022
• Study Completion (Actual): August 31, 2022

Study Registration Dates

• First Submitted: June 9, 2020
• First Submitted That Met QC Criteria: June 9, 2020
• First Posted (Actual): June 11, 2020

Study Record Updates

• Last Update Posted (Actual): February 20, 2024
• Last Update Submitted That Met QC Criteria: February 16, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: treatment seeking in the informal (retail) health sector; malaria diagnostic testing; rational drug use
• Additional Relevant MeSH Terms: Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Malaria; Anti-Infective Agents; Antiprotozoal Agents; Antiparasitic Agents; Antimalarials; Artemisinins; Artemisinin
• Other Study ID Numbers: Pro00104256; 5R01AI141444-02 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No